Welcome to our dedicated page for Mallinckrodt plc news (Ticker: $MNKTQ), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mallinckrodt plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mallinckrodt plc's position in the market.
Rhea-AI Summary
Mallinckrodt plc announced the addition of four seasoned professionals to its Board of Directors, including Paul Bisaro as Board Chair. Siggi Olafsson will continue as President, CEO, and Board Member. The company aims to strengthen its leadership team and continue to deliver for its patients and public health needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mallinckrodt plc announced the presentation of findings from a post hoc analysis of the Phase 3 CONFIRM clinical trial, showing the therapeutic effect of TERLIVAZ in adult patients with hepatorenal syndrome and alcoholic hepatitis. The analysis found that the incidence of verified HRS reversal was significantly higher in patients treated with TERLIVAZ vs. placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mallinckrodt plc (MNK) emerges from Chapter 11 with a strengthened balance sheet and increased financial flexibility. Recent progress includes net sales and adjusted EBITDA growth, FDA acceptance of Acthar® Gel delivery device, positive momentum for Terlivaz®, and growth for Therakos®. The Specialty Generics segment benefits from vertical integration and U.S.-based manufacturing plants, with three FDA abbreviated new drug application approvals. The company reduced its total funded debt by approximately $1.9 billion and satisfied obligations to the Opioid Master Disbursement Trust II.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
Rhea-AI Summary
Mallinckrodt plc (OTCMKTS: MNKTQ) announced 11 scientific abstracts at the AASLD 2023 Liver Meeting, presenting findings from clinical and health economics research with TERLIVAZ (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function. The research details the clinical efficacy, safety, and real-world utility of TERLIVAZ, the first and only FDA-approved product to improve kidney function in adults with HRS with rapid reduction in kidney function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
-
Rhea-AI Summary
Mallinckrodt plc reported a 6.8% increase in net sales for the third quarter of 2023, reaching $497.0 million. The company's financial restructuring plan was approved by the U.S. Bankruptcy Court, positioning it to complete the Irish Examinership and emerge from Chapter 11 in the near term. The company's Specialty Generics segment experienced a 30.2% increase in net sales, while the Specialty Brands segment reported a 5.7% decrease. Adjusted EBITDA for the third quarter was $180.6 million, an 8.7% increase compared to the prior year quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
-
Rhea-AI Summary
Mallinckrodt plc announced that three scientific abstracts evaluating treatment with TERLIVAZ for adults with hepatorenal syndrome (HRS) will be presented at the American Society of Nephrology Kidney Week 2023 Scientific Meeting. TERLIVAZ is the first FDA-approved product indicated to improve kidney function in adults with HRS. The abstracts will explore the impact of TERLIVAZ on patient care, key HRS endpoints, patient comorbidity, and the role of TERLIVAZ in HRS reversal. The studies are sponsored by Mallinckrodt Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
Rhea-AI Summary
Mallinckrodt plc shared findings from health economics research on Acthar Gel for patients with advanced symptomatic sarcoidosis and nephrotic syndrome. The cost-effectiveness analysis showed that Acthar Gel resulted in an incremental cost-effectiveness ratio (ICER) of $134,796 per quality-adjusted life-year (QALY) and $39,179 per QALY over two and three years, respectively. From a societal perspective, Acthar versus standard of care resulted in an ICER of $117,622 per QALY over two years and $21,967 per QALY over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
-
Rhea-AI Summary
Mallinckrodt presents findings from clinical studies and health economic analysis of TERLIVAZ for hepatorenal syndrome treatment outcomes at ACG Annual Scientific Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Mallinckrodt's Plan of Reorganization confirmed by U.S. Bankruptcy Court, positioning the Company to emerge from Chapter 11 by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
Rhea-AI Summary
Mallinckrodt publishes two journal manuscripts supporting Acthar Gel's efficacy and economic benefits in autoimmune and inflammatory diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
Mallinckrodt plc
NYSE:MNKTQ
MNKTQ Rankings
MNKTQ Stock Data
1.60M
5.99M
10.09%
96.64%
13.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Ireland
College Business Technology Park Cruiserath
About MNKTQ
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit